Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review289
Editorial Board191
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis155
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives126
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty107
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer103
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors103
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer99
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in91
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology89
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis87
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming85
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer78
Editorial Board76
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era73
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.68
Optimizing care in early phase cancer trials: The role of palliative care66
Progress toward personalized management of stage II/III triple negative breast cancer63
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches62
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era61
Proton therapy in breast cancer: bridging medical and radiation oncology60
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment59
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis59
De-escalation strategies with targeted therapies in non-small cell lung cancer59
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma57
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications55
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation55
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?55
Uncertainties and controversies in axillary management of patients with breast cancer54
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?54
Editorial Board52
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials52
Editorial Board52
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation51
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC51
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck51
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes50
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations49
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy48
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment47
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?46
Editorial Board45
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]43
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group (TARPSWG)43
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review42
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis42
The immunogram of inflammatory breast cancer42
Overview of BH3 mimetics in ovarian cancer41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design41
Extracellular vesicles and the “six Rs” in radiotherapy41
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier40
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions40
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis39
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada38
Editorial Board36
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma36
Expanding the therapeutic Frontier: Liver transplantation for unresectable colorectal liver metastases36
Long-term surveillance recommendations for young adult cancer survivors35
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers35
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)34
Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma34
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review33
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma33
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis33
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies33
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review33
Editorial Board33
Immunocytokines in cancer treatment: A systematic review32
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer32
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials32
Agnostic drug development revisited32
Malignant ascites: Current therapy options and treatment prospects32
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review32
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review32
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer32
Bone complications of cancer treatment30
Editorial Board30
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life30
Editorial Board30
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review29
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers29
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review29
Genomic distinctions in adolescent and young adult cancer: A comprehensive review29
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]29
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review29
Prognostic role of postoperative circulating tumor DNA in metastatic colorectal cancer treated with curative intent: A systematic review and meta-analysis28
Local control strategies for management of NSCLC with oligoprogressive disease28
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review28
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis28
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes27
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification27
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives27
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?27
Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients27
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review27
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies26
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie26
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project26
Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes25
Pharmacotherapy for leptomeningeal disease in breast cancer25
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer25
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]25
Management of infections in the outpatient care of patients with cancer25
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis25
Strategies for improving detection of circulating tumor DNA using next generation sequencing24
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer24
Evolving immunotherapeutic solutions for triple-negative breast carcinoma24
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis24
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies24
Review: Targeting EZH2 in neuroblastoma24
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review23
Editorial Board23
Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges23
Editorial Board23
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis22
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment22
Editorial Board22
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression21
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives21
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia21
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments21
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis21
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non–small cell lung cancer21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Erratum to “Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review”. [Cancer Treat. Rev. 140 (2025) 103024]21
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review21
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy21
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis21
Editorial Board21
0.1197190284729